Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concizumab prophylaxis in haemophilia A and B patients with inhibitors
2016-000510-30Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hemophilia A and hemophilia B (HB) comparing Concizumab prophylaxis with Control arm (standard-of-care bypassing therapy) (2 arms). Primary endpoint: Number of bleeding episodes. Started Jun 2017; status: completed.
02
Drugs
concizumab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on 2016-000510-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000510-30.